Brief: CVRx Receives FDA Approval For Expanded Labeling Of Barostim
26/12/2023 13:21
Dec 26 (Reuters) - CVRx Inc CVRX.O :
* CVRX RECEIVES FDA APPROVAL FOR EXPANDED LABELING OF
BAROSTIM
Source text for Eikon: ID:nGNX4Wvqvl
Further company coverage: CVRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cvrx
See all newsBrief: Cvrx Appoints John Landry As Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Expedia Group, Parker-Hannifin
CVRx, Inc. reports results for the quarter ended June 30 - Earnings Summary
CVRx Q2 revenue beats estimates, outlook cut on sales force, payer challenges
Brief: CVRx Q2 Revenue USD 15.705 Million Vs. IBES Estimate USD 15.5 Million